{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "FlublokOnePage",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "Flublok COMBINES THE ADVANTAGES OF RECOMBINANT T WITH A HIGHER DOSE 2 4",
      "reason": "does not support claim",
      "original_explanation": "This quote explicitly states that Flublok combines recombinant technology with a higher dose, which supports the claim that it contains a higher amount of HA antigen compared to standard-dose flu vaccines."
    },
    {
      "id": "comp_2",
      "quote": "in January 2024, vaccination with a higher dose recombinant flu vaccine may induce a more robust antibody response than egg based standard dose vaccines.",
      "reason": "does not support claim",
      "original_explanation": "This quote directly links the use of a higher dose recombinant flu vaccine (such as Flublok) to a more robust antibody response compared to standard-dose vaccines, supporting the claim that increased HA antigen content is associated with greater immunogenicity."
    }
  ],
  "model_used": "gpt-4.1"
}